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Abstract
Background:  We have previously demonstrated the clinical efficacy of montelukast in a
randomized double-blind controlled cross-over trial in patients with dyspepsia in association with
duodenal eosinophilia. The mechanism of this clinical response is unknown but could involve a
decrease in eosinophil density or activation.
Methods: Twenty-four dyspeptic patients 8–17 years of age underwent initial blood sampling and
endoscopy with biopsy. Eighteen of these patients had elevated duodenal eosinophil density and
underwent repeat blood sampling and endoscopy following 21 days of therapy with montelukast
(10 mg/day). The following were determined: global clinical response on a 5-point Lickert-type
scale, eosinophil density utilizing H & E staining, eosinophil activation determined by degranulation
indices on electron microscopy, and serum cytokine concentrations. On day 21, pharmacokinetics
and duodenal mucosal drug concentrations were determined.
Results: Eighty-three percent of the patients had a positive clinical response to montelukast with
regard to relief of pain with 50% having a complete or nearly complete clinical response. The
response was unrelated to systemic drug exposure or to mucosal drug concentration. Other than
a mild decrease in eosinophil density in the second portion of the duodenum, there were no
significant changes in eosinophil density, eosinophil activation, or serum cytokine concentrations
following treatment with montelukast. Pre-treatment TNF-α concentration was negatively
correlated with clinical response.
Conclusion: The short-term clinical response to montelukast does not appear to result from
changes in eosinophil density or activation. Whether the effect is mediated through specific
mediators or non-inflammatory cells such as enteric nerves remains to be determined.
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Background
Recurrent abdominal pain is a common complaint
among school-age children that affects up to 15% at any
given time. It represents the most common chronic pain
entity in pediatric patients. These patients frequently are
found to have dyspepsia defined as upper abdominal pain
or discomfort. [1] In fact, eighty-seven percent of children
referred to our clinic for recurrent pain have dyspepsia
(either alone or in combination with irritable bowel syn-
drome). [2] Shaffer, et al, found dyspepsia at similar rates,
being present in 73% of 154 children with recurrent
abdominal pain. [3]
Duodenal eosinophilia has been associated with func-
tional dyspepsia in adults. [4] Previously, we found duo-
denal mucosal eosinophilia in 71% of children
undergoing endoscopy with mucosal biopsy for dyspep-
sia. However, eosinophil density alone may not reflect
disease involvement as density does not necessarily corre-
late with eosinophil activation and many eosinophil-
derived mediators are bioactive in a concentration-
dependent fashion. [5] The degree of degranualtion may
be a better indicator of the disease process rather than
density. In previous investigations, we have found evi-
dence of moderate to extensive eosinophil degranulation
even in biopsies of dyspeptic children with normal
mucosal eosinophil densities. [6]
Montelukast is a competitive antagonist of the cys LT1
receptor with an affinity that is similar to, but lower than
that of leukotriene D4. [7] We and others previously have
reported good clinical response to montelukast in patients
with eosinophilic gastroenteritis. [8-11] Vanderhoof and
Young reported on eight patients with dysphagia,
diarrhea, and/or constipation associated with tissue eosi-
nophilia who had prolonged remission of symptoms with
montelukast therapy. [10] These experiences prompted us
to undertake a double-blinded placebo-controlled cross-
over trial of montelukast in 40 dyspeptic children with
duodenal eosinophilia. In that study, we were able to
demonstrate the superiority of montelukast as compared
to placebo in the relief of pain. [11] Despite an average
duration of pain of nearly 22 months prior to study
enrollment, approximately one-half of the patients
became pain free or nearly pain-free during the two week
course of therapy with montelukast. However, the mech-
anism responsible for the demonstrated clinical efficacy
of montelukast in dyspeptic children with duodenal eosi-
nophilia has not been established. It is possible that the
therapeutic effect might result from a lowering in eosi-
nophil density, alteration of the eosinophil activation
state, blocking leukotrienes released by eosinophils (or
other cells) at their site of action, or any combination of
the aforementioned effects.
Also of interest from our previous study was the finding
that montelukast pharmacokinetics, and thus exposure,
were different than previously observed in children receiv-
ing the drug. Specifically, the average population elimina-
tion t-1/2 for montelukast in our subjects (1.8 hours) was
substantially shorter than mean values for this parameter
(3.4 hours) determined from children without concurrent
intestinal disease. [7,12] While the reasons for this appar-
ent disparity are not clear, it is possible that local monte-
lukast metabolism (i.e. in the small intestine) may vary as
a consequence of disease state. Nonetheless, what remains
to be determined is whether there is a link between sys-
temic and tissue levels and whether an exposure-response
relation can be established for montelukast in pediatric
patients with eosinophilic duodenitis.
Thus, the objectives of the current open-label study were
1) to determine the effect of montelukast on mucosal
eosinophil density and activation in pediatric patients
with eosinophilic duodenitis presenting as dyspepsia; and
2) to evaluate relationships between clinical response, sys-
temic drug exposure, local tissue drug concentration, and
eosinophil density and activation.
Methods
Subjects
Twenty-four subjects ages 8–17 were enrolled in this
study. The sample size was determined to allow for a 25%
drop out rate while maintaining 80% power to detect a
33% decrease in the mean eosinophil density. Subjects
were eligible for inclusion if all of the following criteria
were met: 1) dyspepsia of more than two months dura-
tion, defined as persistent or recurrent pain or discomfort
centered in the upper abdomen, not relieved by defeca-
tion or associated with a change in stool frequency or
form; 2) scheduled for endoscopy following failure to
respond to acid-reduction therapy; and 3) ability to com-
ply with all study procedures.
Subjects were excluded if one or more of the following cri-
teria were met: 1) previous treatment with montelukast;
2) treatment with corticosteroids or oral cromolyn
sodium in the four weeks prior to enrollment; 3) any prior
history, clinical signs/symptoms or biochemical evidence
to suggest clinically significant alteration in hepatic or
renal function; 4) exposure to drugs or natural products
known to induce drug-metabolizing enzymes of the cyto-
chrome P-450 super family, including CYP2C9 (e.g.
rifampin, barbiturates) or CYP3A4 (e.g. rifampin, car-
bamazepine, phenobarbital, phenytoin, nevirapine, St.
John's wort), or to inhibit CYP2C9 (e.g. fluconazole, flu-
voxamine, paroxetine, sertraline, trimethoprim, sulfame-
thoxazole) or CYP3A4 (e.g. azole antifungals, grapefruit
juice, clarithromycin, erythromycin, ciprofloxacin,
antiretroviral agents); or 5) ingestion of Vitamin E supple-BMC Gastroenterology 2009, 9:32 http://www.biomedcentral.com/1471-230X/9/32
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ments. Following endoscopy, subjects were excluded if
peak duodenal bulb eosinophil density was less than 20
cells/high power field (hpf).
The study protocol was approved by the Institutional
Review Board of the participating hospital. Informed
parental permission and subject assent were obtained
prior to initiation of study procedures.
Study Procedures
All subjects underwent an initial endoscopy as part of a
routine clinical evaluation. Standard biopsies (two from
each of the following: lower one-third of the esophagus,
gastric antrum, duodenal bulb, and second portion of the
duodenum) were obtained from all patients for histologic
evaluation and antral biopsies were obtained for rapid
urease testing for Helicobacter pylori. Two additional antral
and two additional duodenal bulb biopsies were obtained
from sights adjacent to the histology biopsies for electron
microscopic (EM) evaluation. These additional EM biop-
sies were discarded for patients who subsequently were
found to have less than 20 eosinophils/hpf on duodenal
bulb biopsies. At the time of endoscopy, blood was
obtained for laboratory analysis as described below.
On study day 1, subjects meeting histologic criteria (more
than 20 eosinophils/hpf) began treatment with 10 mg
montelukast (two 5 mg tablets) orally each morning.
Montelukast (Singulair®, 5 mg oral tablets, Merck & Co.,
Inc.) was supplied by the study sponsor. All subjects were
prescribed age appropriate doses of ranitidine to take
throughout the study. Compliance was assessed by tablet
counts at the end of the treatment period.
On study day 21, treatment response was assessed in two
ways:
1. Global clinical response: The evaluation employed a
Likert-type scale adapted to assess change in pain by sub-
ject report. Pain was the primary symptom in all subjects.
The five pain relief grades were:
Grade 1 Worse – clinical deterioration with increasing
pain intensity and/or frequency.
Grade 2 No change – no increase or decrease in pain
intensity or frequency
Grade 3 Moderate improvement – partial clinical
response with definite improvement in pain, but not
meeting the criteria for a Grade 4 response.
Grade 4 Good – nearly complete relief of symptoms
with minimal residual pain and pain not interfering
with daily activities
Grade 5 Excellent – complete relief of pain
2. Histologic response: Specimens for routine histology
were processed in the usual fashion and stained with
hematoxylin and eosin. These were used to determine cell
density for eosinophils in the esophagus, antrum, duode-
nal bulb, and the second portion of the duodenum. Pre-
and post-treatment specimen slides were mixed together
and evaluated in a blinded fashion by a single observer.
Densities were determined by counting eosinophils
beginning in what appeared to be the most involved area
after scanning the entire specimen. Five consecutive hpfs
(40×, approximately 0.8 square millimeters) were evalu-
ated with the peak count defined as the highest count of
the five fields and the mean count as the average of the
five fields.
Specimens for EM evaluation were processed by the previ-
ously described methodology. [6] Pre- and post- treat-
ment micrographs were mixed and evaluated in a blinded
fashion. Eosinophil activation was evaluated by previ-
ously published methodology, with determination of the
eosinophil activation index (calculated as the percentage
of total granules which are activated). [6]
Laboratory evaluation
ECP: Blood was collected by venipuncture into a 4-mL
Vacutte® (Greiner Bio-One, Kremsmuenster, Austria) tube
without gel or anticoagulant. The tube was gently inverted
8 times then placed in a 26°C ± 1°C water bath for 1 hour
± 5 min. The tube was then centrifuged at 3,000 × g for 15
min at 4°C. Serum was harvested and stored at -80°C
until analysis. Serum ECP was quantitated using a com-
mercially available fluorescent enzyme-immunoassay
platform (ImmunoCAP™, Phadia AG, Uppsala, Sweden)
following the manufacturer's directions.
Cytokines: Blood was collected by venipuncture into a
chilled 3-mL Vacutainer® (BD, Franklin Lakes, NJ) tube
containing EDTA. The tube was gently inverted 8 times
then centrifuged at 3000 × g for 15 min at 4°C. Plasma
was harvested and stored at -80°C until analysis. Plasma
cytokines were quantitated using a commercially availa-
ble multi-plex bead array kit, Cytokine 25-plex Ab Bead
Kit, Hu (BioSource™, Carlsbad, California, USA) with the
Luminex™ platform (Austin, Texas, USA). Cytokine analy-
ses were performed following the manufacturer's direc-
tions with one modification. The lower limit of
quantitation was extended for most of the analytes,
including IL-4, IL-5, IL-8, TNF-α, MCP-1 by including anBMC Gastroenterology 2009, 9:32 http://www.biomedcentral.com/1471-230X/9/32
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additional 3-fold serial dilution of the rehydrated stand-
ards (1:1458 dilution) in the stand curve.
Pharmacokinetic Analysis
On day 21, all patients reported to the GI procedure room
three hours prior to their endoscopy. An intravenous cath-
eter was placed for the procedure. At 2.5 hours prior to the
procedure, patients received two 5 mg montelukast tablets
with up to 2 ounces of water and the time was recorded.
Blood samples were obtained at 1, 2.5, and 6 hours post-
dosing. Blood samples were collected in glass tubes con-
taining sodium heparin and were mixed by manual inver-
sion. Tubes were centrifuged (2,500 × g, 15 minutes,
4°C). Plasma was removed by aspiration and placed into
polypropylene vials and stored at -80°C. At the time of
endoscopy (approximately 2.5 hours post-dosing), multi-
ple duodenal mucosal biopsies (approximate aggregate
tissue yield = 0.5 gm) were obtained for determination of
tissue drug concentration. Tissue samples were placed in
polypropylene vials and stored at -80°C until analysis. All
plasma and tissue drug concentrations were determined
by the manufacturer (Merck) using a validated high per-
formance liquid chromatographic method with fluores-
cence that has been used to support two previous
pharmacokinetic studies of montelukast conducted in
pediatric patients, both of which have successfully used
the aforementioned approach for pharmacokinetic data
analysis. [11,12]
The montelukast plasma concentration data from all sub-
jects was fit using a one compartment population phar-
macokinetic model with first order absorption and
elimination. The pharmacokinetic model was initially
parameterized using data from our previous investigation
conducted in pediatric patients with functional dyspepsia.
[11] Goodness of fit for the pharmacokinetic model was
assessed using standard criteria (e.g., Akaike an Schwartz
Information Criteria, objective function and the coeffi-
cients of variation for estimated parameters), the distribu-
tion of weighted residual estimates and the association
between the observed and predicted plasma concentra-
tions. Estimates of apparent absorption rate constant
(Ka), terminal elimination rate constants (λz) and appar-
ent volume of distribution (Vd/F) were determined for
each child using the algorithms contained in the Kinetica
(version 4.1.1, InnaPhase Corporation, Inc, Philadelphia,
Pennsylvania, USA) software package. Estimates of appar-
ent oral clearance (Cl/F) and area under the plasma con-
centration vs. time curve at steady state (AUC) were
derived using the individual parameter estimates.
Statistical Analysis
Pre- and post-treatment eosinophil densities, degranula-
tion indices, and ECP and cytokine concentrations,
respectively, were compared using paired t-tests. These
tests were compared for the group as a whole and sepa-
rately for patients < 12 years of age and clinical responders
(≥ grade 3), respectively. Pearson correlation coefficients
were determined for mucosal densities, degranulation
indices, laboratory parameters, and clinical response
grade. Pre-treatment laboratory parameters were com-
pared by response grade via one-way ANOVA. Statistical
analysis of pharmacokinetic data utilized a combination
of approaches to assess the potential interactions between
montelukast disposition and response. Relationships
between continuous variables (eg., dose, ECP concentra-
tions) were evaluated by linear and nonlinear regression
techniques. A two-tailed, Student's t test was used to eval-
uate differences in disposition (eg. plasma vs. tissue con-
centrations) and response associated with gender as well
as to examine exposure-response relationships for sub-
jects classified by pain relief assessment. All statistical
analyses were completed using the SSPS software package
(version 15.0, SPSS Inc., Chicago, IL) and used a signifi-
cance limit of α = 0.05.
Results
Subjects
Nineteen of the 24 subjects (79%) met the criteria of peak
duodenal bulb eosinophil density of > 20/hpf. One of
these patients subsequently was dropped from analysis
for non-compliance with the study procedures as he had
received less than one half of the medication at the 3 week
re-evaluation visit. This resulted in 18 patients undergoing
repeat endoscopic examination and pharmacokinetic
studies. Seventy-two percent of the final sample was
female. Subjects ranged in age from 9 to 16 years with a
mean of 12.9 ± 2.1 years. Twenty-two percent of the
patients reported a history of seasonal allergies. No
patients reported food allergies but one patient had a his-
tory of crampy abdominal pain with milk ingestion. The
family history was positive for allergies in 72% (13/18).
Clinical Response
No patients experienced deterioration while on montelu-
kast. Three patients reported no change in pain during
therapy while fifteen (83%) had a partial to complete clin-
ical response. The percentages of subjects experiencing
each level of clinical response are shown in Figure 1.
Mucosal Response
The mean and peak eosinophil densities before and after
treatment are shown in Table 1. Only a mild decrease in
the peak density in the second portion of the duodenum
reached significance (p = 0.04). Pre- and post-treatment
densities did not differ when analyzed for clinical
responders only. For subjects less than 12 years of age, the
mean bulb eosinophil density was decreased post-treat-
ment (17.2 ± 11.7 vs. 26.2 ± 15.9, p = .01) and there wasBMC Gastroenterology 2009, 9:32 http://www.biomedcentral.com/1471-230X/9/32
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a trend towards a decrease in peak bulb density (23.2 ±
11.4 vs. 36.0 ± 24.4, p = .07).
Pretreatment degranulation indices revealed mild degran-
ulation (< 20%) in 5.6%, moderate degranulation (20–
60%) in 66.7%, and extensive degranulation (> 60%) in
27.7% of patients in both the antrum and duodenal bulb.
Comparing pre- and post-treatment specimens, there were
no significant differences in the mean degranulation indi-
ces in either the antrum (47.8 ± 23.0 vs. 46.9 ± 24.1%) or
the duodenal bulb (47.7 ± 24.3 vs. 57.1 ± 21.2%).
Laboratory Evaluation
Eosinophil cationic protein and cytokine concentrations
before and after treatment are shown in Table 2. There
were no significant differences between pre- and post-
treatment concentrations. Pre- and post-treatment con-
centrations also did not differ either for age group (<12 or
≥ 12 years) or for clinical responders.
Pre-treatment ECP concentration was significantly corre-
lated with pre-treatment antral mean (r = 0.686, p = .002)
and peak (r = 0.697, p = .001) eosinophil density. Post-
treatment, there were no significant correlations between
laboratory parameters and eosinophil density.
The percentage of patients exhibiting each grade of pain relief after treatment with montelukast Figure 1
The percentage of patients exhibiting each grade of pain relief after treatment with montelukast.
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Table 1: Mean and Peak eosinophil densities before and after treatment with montelukast.
Pre-treatment Post-treatment P Value
Esophagus: Mean 0.24 ± 0.49 0.40 ± 1.3 NS
Peak 0.72 ± 1.4 0.78 ± 2.1 NS
Antrum: Mean 10.3 ± 10.1 8.9 ± 4.8 NS
Peak 17.2 ± 14.9 16.7 ± 10.7 NS
Duodenal Bulb: Mean 21.2 ± 11.5 18.4 ± 9.7 NS
Peak 29.7 ± 17.1 25.8 ± 12.9 NS
2nd portion duodenum: Mean 27.9 ± 12.7 22.7 ± 9.3 NS
Peak 39.7 ± 14.2 31.6 ± 14.9 .04BMC Gastroenterology 2009, 9:32 http://www.biomedcentral.com/1471-230X/9/32
Page 6 of 10
(page number not for citation purposes)
Only pre-treatment TNF-α concentration differed by clin-
ical response grade (F = 6.05, p = .007) although there was
a trend towards a difference for MCP-1 (F = 2.91, p = .07).
Pre-treatment TNF-α was negatively correlated with clini-
cal response grade (r = -0.519, p = .027), but positively
correlated with MCP-1 (r = 0.805, p < .001) and IL8 (r =
0.570, p = .01). Other significant pre-treatment correla-
tions for cytokines included IL4/IL5 (r = 0.916, p < .001),
IL4/IL8 (r = 0.774, p < .001), IL5/IL8 (r = 0.572, p = .01),
and IL8/MCP-1 (r = 0.629, p = .005).
Pharmacokinetics
The composite montelukast plasma concentration vs.
time data from the 18 evaluable subjects are illustrated in
Figure 2. As expected, a significant degree of variability
was observed in the plasma concentrations owing to a
nearly three-fold difference in weight-corrected dose
between the participants (range: 0.11–0.30 mg/kg). How-
ever, dose (mg/kg) accounted for only 44% of the varia-
bility observed in the 2.5 hour plasma concentration
(C2.5) and was not predictive of the plasma concentra-
tions observed at 1 (C1) and 6 hours (C6).
Individual pharmacokinetic parameter estimates along
with relevant demographic data, are contained in Table 3.
The area under the plasma concentration vs. time curve
(AUC) was calculated for each child using standard equa-
tions incorporating dose, Vd/F and Kel. The average (SD)
AUC was 4947.4 (1363.4) ng*hr/mL. AUC was highly
correlated with post-peak plasma concentrations (r2  =
0.75 and 0.83 at 2.5 and 6 hours, respectively); however,
only a modest, albeit significant, relationship between
dose and total body exposure (AUC) was observed (r2 =
0.26, p = 0.03). In contrast, we observed no significant
relationship between tissue concentrations at 2.5 hours
and dose, plasma concentration, or AUC. Similarly, there
were no apparent associations between age or gender and
any of the montelukast pharmacokinetic parameter esti-
mates.
We observed no relationship between montelukast dose
or exposure (plasma concentration or AUC) and clinical
responder status. Similarly we were unable to establish an
association between montelukast exposure and changes
in the histologic or biochemical markers of disease over
the course of therapy. We did observe a positive linear
relationship between C6 and the change in ECP between
baseline and post-treatment periods (r2 = 0.40, p = 0.016);
however, the relevance of this finding is unclear.
Discussion
Functional dyspepsia has been associated with duodenal
eosinophilia in adults. [4] In children with dyspepsia,
mucosal eosinophilia is a common finding and moderate
to extensive eosinophil degranulation has been demon-
strated. [6,11] Similar to previous reports, we found ele-
vated duodenal eosinophil density (peak > 20 cells/hpf)
in 79% of the patients in the current study. [11] Previously
we reported moderate (20–60%) duodenal eosinophil
degranulation in 65% and extensive (> 60%) degranula-
tion in 30% of children with dyspepsia. [6] This is very
similar to the degree of duodenal eosinophil degranula-
tion in the current study which was moderate in 67% and
extensive in 28%. In addition, moderate or extensive
antral eosinophil degranulation was seen in 94% of
patients in the current study. Findings of frequent
mucosal eosinophilia and a high degree of degranulation
would implicate eosinophils in the generation of dyspep-
sia in a subset of patients.
We previously evaluated the clinical response to montelu-
kast in a double-blind, placebo-controlled, cross-over trial
in children with dyspepsia associated with duodenal eosi-
nophilia. [11] Montelukast demonstrated superiority to
placebo in relief of pain. A positive clinical response was
seen in 62.1% of patients receiving montelukast as com-
pared to 32.4% receiving placebo. Despite a mean dura-
tion of symptoms of nearly 22 months, approximately
50% of patients became pain-free or nearly pain-free
(grade 4 or 5 response) over a two-week treatment course
with montelukast. The mechanism responsible for this
treatment response is not known. Montelukast would
have the potential to result in improved symptoms by
decreasing eosinophil density, decreasing eosinophil acti-
vation, and/or blocking leukotrienes at a site of action not
related to eosinophils, such as enteric nerves. The current
study was undertaken to evaluate potential mechanisms
of action.
In the current study, the clinical response was strikingly
similar to the previous trial. A positive clinical response
was seen in 83% of patients with 50% becoming pain-free
or nearly pain-free (grade 4 or 5) at the end of 3 weeks on
treatment. We enrolled patients with a peak duodenal
bulb eosinophil density > 20 cells/hpf as we were able to
demonstrate superiority to placebo in patients with 20–
29 cells/hpf in the previous trial where a positive response
was seen in 84% of patients (vs. 42% with placebo). In the
Table 2: ECP and cytokine concentrations before and after 
treatment with montelukast.
Pre-treatment Post-treatment
ECP 10.6 ± 6.8 12.2 ± 9.0
IL-4 10.5 ± 5.7 11.7 ± 9.7
IL-5 1.8 ± 1.2 2.0 ± 2.1
IL-8 5.5 ± 7.8 8.5 ± 14.2
MCP-1 277.0 ± 199.7 289.3 ± 149
TNF-α 12.2 ± 15.3 10.2 ± 11.6
*all differences non-significantBMC Gastroenterology 2009, 9:32 http://www.biomedcentral.com/1471-230X/9/32
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Individual montelukast plasma concentration vs. time data Figure 2
Individual montelukast plasma concentration vs. time data.
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Table 3: Demographic Data and Pharmacokinetic Parameter Estimates for Montelukast
Subject No. Age
(yr)
Dose
(mg/kg)
Weight
(kg)
Ka
(1/hr)
Vd/F
(L/kg)
Kel
(1/hr)
1 13 0.188 53.3 0.532 0.08 0.334
3 14 0.166 60.2 0.577 0.06 0.399
5 10 0.293 34.1 0.609 0.14 0.475
7 14 0.125 80.1 0.545 0.09 0.354
8 13 0.272 36.7 0.555 0.11 0.386
9 9 0.22 45.4 0.498 0.11 0.293
10 11 0.305 32.8 0.553 0.13 0.396
11 14 0.14 71.2 0.554 0.10 0.375
12 11 0.305 32.8 0.507 0.14 0.354
13 16 0.176 56.9 0.544 0.14 0.401
14 15 0.187 53.6 0.535 0.13 0.369
15 15 0.169 59.1 0.570 0.10 0.396
17 10 0.173 57.7 0.538 0.11 0.355
19 11 0.152 65.6 0.546 0.08 0.353
20 13 0.223 44.8 0.548 0.13 0.394
21 15 0.115 87.3 0.565 0.11 0.395
22 14 0.19 52.6 0.605 0.08 0.424
23 15 0.123 81.2 0.538 0.09 0.345
Mean (SD) 12.9 (2.1) 0.20 (0.06) 55.9 (16.7) 0.55 (0.03) 0.11 (0.02) 0.38 (0.04)BMC Gastroenterology 2009, 9:32 http://www.biomedcentral.com/1471-230X/9/32
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short term, the clinical response appears to be independ-
ent of changes in eosinophil density or activation. The
only change in density over treatment was a mild decrease
in the peak eosinophil density in the second portion of
the duodenum and there was no relationship between
changes in eosinophil density and the degree of clinical
response. It is possible that density might have been
affected with a longer course of therapy or that a larger
dose is required as has been seen with eosinophilic
esophagitis. [13] While we were unable to demonstrate
differences in eosinophilic activation, this may be the
result of a lack of sensitivity of the method employed.
While degranulation indices are general indicators of acti-
vation, they may have limited usefulness in evaluating
specific pathophysiologic relationships. Eosinophils pro-
duce dozens of mediators which may be selectively
released and which have varying physiologic actions. Fur-
ther work is necessary to determine if montelukast alters
the release of specific mediators which in turn affect the
clinical response.
The mechanisms responsible for the clinical response to
montelukast may involve inflammatory cells other than
eosinophils or may involve leukotriene receptors on non-
inflammatory cells such as enteric neurons. The clinical
effect may be mediated through mast cells which have
been implicated in functional gastrointestinal disorders
and which contain cysteinyl-leukotriene receptors. [14]
Mast cell density has been found to be increased in adults
with functional dyspepsia and to be associated with
delayed gastric emptying and gastric dysrhythmia in chil-
dren with functional dyspepsia. [15,16] Cysteinyl-leukot-
rienes (cys-LTs) have been shown to alter mast cell
function. For example, cys-LTs can induce IL-5 and TNF-α
production in primed mast cells, an effect blocked by cys-
LT inhibition. [17] Montelukast has been shown to signif-
icantly reduce the number of TNF-α positive mast cells
and TNF-α concentrations in an arthritis model. [18]
Montelukast's effect may also involve other inflammatory
cells as montelukast has been shown to down regulate
human monocyte chemotaxis induced by MCP-1. [19]
The clinical effect of montelukast also could result from
modulation of neuromuscular function. Leukotriene
receptors are expressed on spinal sensory nerve terminals
giving leukotrienes the potential to increase the sensitivity
of intestinal sensory nerves during inflammation. Cys-LTs
have been shown to increase depolarization and excitabil-
ity of enteric neurons and to have a pro-contractile effect
on esophagus, stomach, small bowel, colon, and gallblad-
der. [20-27] These effects appear to be mediated, in part,
through cholinergic pathways. [26,27]
While others have demonstrated a decrease in serum con-
centrations of ECP, IL5, IL8, and TNF-α with montelukast
therapy in asthma, allergic rhinitis, and cystic fibrosis, we
were unable to show any decrease of these in children
with dyspepsia. [28-30] Certainly the serum concentra-
tions may not be reflective of gastrointestinal mucosal
concentrations. We did, however, find a negative correla-
tion between pre-treatment TNF-α concentrations and the
degree of clinical response and there was a trend towards
a negative relation between pre-treatment MCP-1 concen-
trations and clinical response. TNF-α, MCP-1, and IL8
concentrations were significantly correlated with each
other. The clinical significance of these findings is not
known. Inhaled TNF-α has been shown to increase spu-
tum eosinophils without increasing IL4 or IL5 concentra-
tions in asthmatics. [31] TNF-α has been found to be a
vital component for chemokine generation in an eosi-
nophil cell line and can promote a Th1 or Th2 response
depending on other chemokines present in the microen-
vironment. [32] MCP-1 is chemotactic for eosinophils
and mast cells (as well as other inflammatory cells) pro-
moting histamine and leukotriene release. [33] High
doses of montelukast in vitro have been shown to inhibit
production of TNF-α and MCP-1 in peripheral blood
mononuclear cells. [33] The clinical effects of montelu-
kast may be exerted by modulation of the inflammatory
response downstream from leukotrienes.
The mean pharmacokinetic parameter estimates observed
in this investigation were strikingly similar to those
observed in our earlier examination of montelukast in
children with functional dyspepsia. [11] We continue to
observe a significant degree of variability in total body
exposure across this age group (range: 2636.3 to 7021.6
ng*hr/mL) which does not diminish when AUC is cor-
rected for differences in weight-normalized dose. In con-
trast to our previous investigation, we were unable to
detect an influence of age on montelukast pharmacoki-
netic parameters including distribution volume. This is
likely a function of a narrower age-range in the current
cohort than in our previous investigation. Finally, this
investigation confirms that the terminal half-life for mon-
telukast appears shorter in children with functional dys-
pepsia. As denoted in our earlier study this may reflect
disease-dependent changes in presystemic bioavailability
or may simply reflect errors in parameter estimation using
a population-based pharmacokinetic approach. Given the
shorter half-life, it is possible that different effects on
inflammation might be seen with different treatment
strategies such as twice daily dosing.
Conclusion
While montelukast therapy is associated with relief of
pain in children with dyspepsia who have associated duo-
denal eosinophilia, this response is not related to systemic
drug exposure or local tissue concentrations. Also, the
short-term clinical response does not appear to result
from changes in tissue eosinophil density or global eosi-BMC Gastroenterology 2009, 9:32 http://www.biomedcentral.com/1471-230X/9/32
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nophil activation. Whether the effect is mediated through
alteration in secretion of specific mediators or an effect on
non-inflammatory cells such as enteric neurons remains
to be determined.
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